What are the benefits of using home-administered ketamine troches compared with the FDA-approved esketamine nasal spray (Spravato) for treatment‑resistant depression?

Home Ketamine Troches vs. Spravato: Clinical Comparison

Home-administered ketamine troches are not supported by FDA approval or high-quality evidence for treatment-resistant depression, whereas Spravato (esketamine nasal spray) is FDA-approved with mandatory supervised administration and demonstrated efficacy in controlled trials 1.

Critical Regulatory and Safety Distinction

The fundamental difference is that Spravato requires supervised administration in a healthcare setting with mandatory 2-hour post-dose monitoring due to risks of sedation, dissociation, respiratory depression, and abuse potential 1. This is enforced through a REMS (Risk Evaluation and Mitigation Strategy) program. Home ketamine troches circumvent these safety protocols entirely and lack FDA approval for any psychiatric indication.

Spravato's Supervised Administration Requirements:

• Mandatory healthcare provider supervision during each treatment session
• Continuous monitoring for at least 2 hours post-administration
• Pulse oximetry monitoring for respiratory status
• Blood pressure assessment before dosing and at 40 minutes post-dose
• Patient cannot leave until clinically stable 1

Home ketamine troches eliminate these critical safety measures, creating substantial medicolegal and patient safety concerns.

Evidence Quality and Efficacy

Spravato (Esketamine):

• FDA-approved for treatment-resistant depression as monotherapy or adjunctive therapy 1
• Recent 2025 RCT demonstrated esketamine monotherapy efficacy with effect sizes of 0.48 (56mg) and 0.63 (84mg) versus placebo at day 28 2
• Rapid onset within 24 hours of first dose (significant improvement at day 2) 2
• Standardized dosing: 56mg or 84mg intranasal, twice weekly for 4 weeks (induction), then weekly or every 2 weeks (maintenance) 1

Ketamine Troches:

• No FDA approval for any psychiatric indication
• No published RCTs specifically evaluating sublingual/oral ketamine troches for depression
• Dosing, bioavailability, and pharmacokinetics are unstandardized and poorly characterized
• The evidence base for ketamine in depression pertains almost exclusively to intravenous ketamine (0.5 mg/kg over 40 minutes) 3, not oral/sublingual formulations

Comparative Effectiveness Data

A 2023 observational study comparing IV ketamine to intranasal esketamine found similar response and remission rates, but IV ketamine achieved remission faster (fewer treatments required) 4. However, this compared IV ketamine—not oral troches—to esketamine. The pharmacokinetics of oral/sublingual ketamine differ substantially from IV administration, with lower bioavailability and unpredictable absorption.

There are no head-to-head studies comparing home ketamine troches to Spravato, and the 2026 EQUIVALENCE trial protocol specifically compares IV ketamine to intranasal esketamine, not oral formulations 5.

Practical Disadvantages of Home Ketamine Troches

Safety Concerns:

• No monitoring for dissociation, sedation, or respiratory depression—all documented risks with ketamine 1
• Abuse and misuse potential without supervision 1
• Risk of unsupervised adverse events including falls, impaired judgment, and respiratory compromise
• No standardized assessment of blood pressure changes (ketamine can cause acute hypertensive episodes)

Clinical Limitations:

• Unpredictable bioavailability and absorption via oral/sublingual route
• No established dosing protocols or titration guidelines
• Lack of quality control in compounded formulations
• No data on long-term safety or durability of response
• Insurance typically does not cover compounded ketamine troches

Medicolegal Risk:

• Prescribing off-label ketamine for home use without monitoring infrastructure exposes clinicians to significant liability
• Violates the standard of care established by FDA approval of supervised esketamine

Clinical Algorithm for Treatment Selection

For treatment-resistant depression requiring rapid-acting glutamatergic intervention:

1. First-line: Spravato (esketamine nasal spray) with supervised administration 1

   • FDA-approved with established safety protocols
   • Standardized dosing and monitoring
   • Insurance coverage more likely
   • REMS program ensures appropriate patient selection and monitoring

2. Alternative: IV ketamine in supervised clinical setting 4

   • May achieve remission faster than esketamine
   • Requires infusion center or clinic with monitoring capability
   • Off-label but supported by substantial evidence base 3

3. Not recommended: Home ketamine troches

   • No FDA approval
   • No evidence base for this formulation/route
   • Eliminates critical safety monitoring
   • Substantial medicolegal risk

Common Pitfalls to Avoid

• Do not assume oral/sublingual ketamine has equivalent efficacy to IV ketamine—the evidence for ketamine's antidepressant effects is based on IV administration 3
• Do not prescribe home ketamine troches as a convenience alternative to supervised Spravato—the supervision requirement exists for patient safety, not administrative burden
• Do not rely on patient preference alone—the abuse potential and dissociative effects require clinical oversight 1

The only evidence-supported "benefit" of home ketamine troches is convenience, which is vastly outweighed by safety concerns, lack of efficacy data, and regulatory/medicolegal risks. For treatment-resistant depression requiring glutamatergic intervention, Spravato with appropriate supervision represents the evidence-based standard of care.